Summary: Aetna modified CPB 1017, its coverage policy for elivaldogene autotemcel (Skysona), effective April 9, 2026. Here's what billing teams need to know before submitting claims for this high-cost gene therapy.
Aetna, a CVS Health company, updated CPB 1017 governing Skysona — the gene therapy approved for early, active cerebral adrenoleukodystrophy (CALD). This is not a routine policy tweak. Gene therapy billing carries some of the highest financial exposure in the specialty space, and any shift in Aetna's medical necessity criteria or prior authorization requirements will hit your revenue cycle hard if you're not prepared. The policy does not list specific CPT or HCPCS codes in the data available at publication — see the codes section below for details.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Elivaldogene Autotemcel (Skysona) — CPB 1017 |
| Policy Code | CPB 1017 |
| Change Type | Modified |
| Effective Date | April 9, 2026 |
| Impact Level | High |
| Specialties Affected | Neurology, Hematology, Stem Cell Transplant, Pediatric Specialty Centers |
| Key Action | Review your prior authorization workflows and medical necessity documentation for Skysona before submitting any claims dated on or after April 9, 2026 |
Aetna Elivaldogene Autotemcel Coverage Criteria and Medical Necessity Requirements 2026
The Aetna elivaldogene autotemcel coverage policy under CPB 1017 governs one of the most expensive single-treatment therapies in the market. Skysona carries a wholesale acquisition cost well above $3 million. Getting a claim denied on medical necessity grounds is not a billing inconvenience — it's a catastrophic revenue event.
Elivaldogene autotemcel is an ex vivo gene therapy. It works by inserting a functional copy of the ABCD1 gene into a patient's own hematopoietic stem cells. The FDA approved it in 2022 for boys ages four to 17 with early, active CALD who have a brain lesion score of four or less and no HLA-matched sibling donor available for stem cell transplant.
Aetna's CPB 1017 Aetna system coverage policy historically tracks closely to FDA-labeled indications for gene therapies, but payers routinely add additional medical necessity layers on top of FDA approval. That's the risk here. A patient can meet FDA criteria and still get denied if your documentation doesn't match Aetna's specific coverage criteria for CPB 1017.
Because the policy was modified on April 9, 2026, and the detailed criteria within the updated document aren't fully reproduced in the data available at publication, you need to pull the current version of CPB 1017 directly from Aetna's clinical policy bulletins before submitting any claim. Do not rely on the prior version of this policy — modifications to gene therapy policies often change eligibility thresholds, required prior testing, or documentation standards in ways that aren't telegraphed in advance.
Prior authorization is required for Skysona under Aetna. This is not optional and not negotiable. Gene therapies like Skysona sit in a category where no payer approves claims without prior auth. Your team should treat any Skysona claim without a valid prior authorization number as dead on arrival.
Medical necessity documentation for this therapy must support the clinical criteria Aetna specifies. Expect Aetna to require documentation of brain lesion score, confirmation of early and active CALD status, absence of an HLA-matched sibling donor, and patient age. If your center does not already have a standardized pre-submission checklist for Skysona, build one now — before the April 9, 2026 effective date becomes your problem.
Aetna Elivaldogene Autotemcel Exclusions and Non-Covered Indications
Gene therapy coverage policies almost always carry explicit exclusions. For Skysona specifically, the clinical context tells you where the walls are.
Aetna has historically considered elivaldogene autotemcel not covered — or experimental and investigational — for patients who fall outside the FDA-approved indication. That means adult patients, patients with advanced CALD (brain lesion score above four), and patients who have an available HLA-matched sibling donor would likely not meet coverage criteria. Treating an off-label population without a separate prior authorization pathway is a near-certain route to a claim denial.
Experimental and investigational designations for gene therapies are common when a therapy is used for conditions beyond its approved indication. If your clinical team is considering Skysona for any use outside early CALD in pediatric males, loop in your compliance officer before submission. The financial exposure of a denied gene therapy claim — and the recoupment risk if one slips through — is too high to handle through standard appeals alone.
Because the April 9, 2026 modification may have shifted how Aetna defines covered vs. non-covered indications, do not assume the prior version of CPB 1017 reflects current exclusion criteria. Pull the live document.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Early, active CALD in males ages 4–17, brain lesion score ≤4, no HLA-matched sibling donor | Likely Covered (per FDA approval and historical CPB 1017 alignment) | Not specified in available policy data | Prior authorization required; full documentation of lesion score and donor status needed |
| CALD in adults | Likely Not Covered / Experimental | Not specified in available policy data | Outside FDA-approved age range |
| Advanced CALD (brain lesion score >4) | Likely Not Covered / Experimental | Not specified in available policy data | Exceeds FDA-labeled indication |
| CALD with available HLA-matched sibling donor | Likely Not Covered / Experimental | Not specified in available policy data | Stem cell transplant is the standard of care when matched donor is available |
| Off-label use for other leukodystrophies or conditions | Likely Not Covered / Experimental | Not specified in available policy data | Outside approved indication; payer-level appeal or compassionate use pathway required |
Important: These indications reflect the FDA label and historical CPB 1017 alignment. They are not a substitute for the current policy text. Verify coverage status directly against the April 9, 2026 version of CPB 1017 at Aetna's clinical policy bulletins before billing.
Aetna Elivaldogene Autotemcel Billing Guidelines and Action Items 2026
Gene therapy billing is where revenue cycle teams either get organized or get burned. Here's what to do now.
| # | Action Item |
|---|---|
| 1 | Pull the updated CPB 1017 document from Aetna immediately. The modification is effective April 9, 2026. Any claim for Skysona submitted on or after that date must reflect the updated criteria. Access the policy directly at Aetna's clinical policy bulletin portal or through your payer contract representative. |
| 2 | Verify prior authorization requirements before any infusion date. For Skysona, prior auth is mandatory. Confirm the authorization covers the specific date of service, the facility, and the treating provider. A prior auth issued under the old policy version may not satisfy requirements under the modified CPB 1017. |
| 3 | Audit your medical necessity documentation checklist against the updated policy. Your clinical team needs to document brain lesion score (≤4), age (4–17), confirmed CALD activity, and absence of an HLA-matched sibling donor. If the April 9, 2026 modification added new documentation requirements, your existing templates may be incomplete. |
| 4 | Check reimbursement rates and any applicable fee schedule changes with Aetna. Gene therapies often have separately negotiated reimbursement arrangements — either through manufacturer-payer outcomes-based contracts or specialty pharmacy carve-outs. Confirm how Skysona reimbursement flows under your specific Aetna contract. A policy modification sometimes triggers a reimbursement structure review. |
| 5 | Identify all pending Skysona cases and flag them for re-review. If you have patients mid-authorization process as of April 9, 2026, those cases need a fresh look. Don't assume an in-progress prior auth under the old policy criteria will be honored under the modified coverage policy. |
| 6 | Brief your clinical and coding teams on the effective date. Your coders need to know that CPB 1017 changed on April 9, 2026. Your physicians need to know that documentation requirements may have shifted. A 15-minute internal huddle before the first post-modification claim goes out is worth more than three appeals filed after the fact. |
| 7 | If your volume of Skysona cases is more than one or two per year, talk to your compliance officer. The financial exposure on a single denied gene therapy claim can exceed $3 million. At that dollar level, your standard billing team review is not enough. Your compliance officer and — depending on your contract structure — your legal counsel should have eyes on any CPB 1017 interpretation questions. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Elivaldogene Autotemcel Under CPB 1017
The available policy data for this modification does not list specific CPT, HCPCS, or ICD-10 codes. This is common for gene therapy policies, where coding often involves Q-codes assigned after FDA approval, facility-specific billing arrangements, or codes that vary by payer contract.
Do not use codes from prior policy versions or third-party code lists without verifying against the current CPB 1017 document. Gene therapy coding is evolving, and using an outdated or incorrect code on a claim of this magnitude will result in a denial that may take months to resolve.
To identify the correct codes for elivaldogene autotemcel billing under Aetna, take these steps:
- Contact your Aetna provider relations representative and request the current applicable codes under CPB 1017
- Check with your specialty pharmacy partner — Skysona is dispensed through a limited distribution network, and your pharmacy contact often has current billing code guidance
- Review the manufacturer (bluebird bio) billing and coding support resources, which are updated to reflect current payer requirements
- Consult your coding team or billing consultant for any Q-code or J-code assignments active for Skysona under Aetna's current fee schedule
Until you have confirmed codes from the current CPB 1017 or direct Aetna guidance, do not submit a claim.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.